ScripDomestic licensing deals for homegrown innovative drugs in China posted a spike in July, as drug makers with established commercialization capabilities replenished their late-stage pipelines and resea
ScripInitial public offerings (IPOs) for innovative, drug-focused biotechs have remained elusive in the Chinese mainland well into the second half of 2024, since the country’s top securities regulator put
ScripAmid a sweeping tightening of securities regulatory policies since late 2023, there has been a dearth of initial public offerings for bioventures in the Chinese mainland. But Hong Kong has just welcom